omniture
成都先导药物开发股份有限公司 CHENGDU HITGEN LTD

Latest News

Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program

* Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery p...

2024-08-22 21:30 1987

Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery, Upcoming Webinar Hosted by HitGen and Xtalks

CHENGDU, China, July 16, 2024 /PRNewswire/ -- "Evolving DNA-Encoded Library Technology and Its Appl...

2024-07-16 23:55 2132

Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology

CHENGDU, China, Feb. 20, 2024 /PRNewswire/ -- Hox Therapeutics Ltd ("Hox") a private biotechnology ...

2024-02-20 22:30 1699

SGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, Sept. 28, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. (...

2023-09-28 21:30 1563

HitGen Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics

CHENGDU, China, Aug. 10, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("...

2023-08-10 21:30 1941

HitGen launches a newly upgraded version of OpenDEL™, a self-service screening kit, to facilitate innovative drug discovery research

CHENGDU, China, June 26, 2023 /PRNewswire/ -- HitGen Inc. ("HitGen", SSE: 688222.SH) has recently l...

2023-06-26 21:30 2460

HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics

CHENGDU, China, May 18, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("H...

2023-05-18 21:30 2405

HitGen Announces Research Agreement with Nitrase Therapeutics Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, Dec. 11, 2022 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("...

2022-12-12 10:10 1971

Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology

CAMBRIDGE, England and COPENHAGEN, Denmark, Sept. 28, 2022 /PRNewswire/ -- Vernalis Research ("Vern...

2022-09-28 16:00 1616

Vernalis Research, a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. announce a research collaboration in the field of anti-infectives

CHENGDU, China, Sept. 5, 2022 /PRNewswire/ -- Vernalis Research ("Vernalis"), a fully owned subsidi...

2022-09-05 16:00 2721

"OpenDEL®3.0 - DRUG DISCOVERY PARTNER" webinar offered by HitGen and Endpoints News coming up on Thursday 4th August

CHENGDU, China, Aug. 1, 2022 /PRNewswire/ -- "OpenDEL®3.0 – DRUG DISCOVERY PARTNER" webinar will be...

2022-08-01 22:00 1952

LoQus23 and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, July 27, 2022 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("...

2022-07-27 16:30 1999

HitGen and UPPTHERA Extend PROTAC Research Collaboration after Hit Finding Success on Undruggable Targets

CHENGDU, China, April 6, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STA...

2022-04-06 22:30 2194

HitGen Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China, March 17, 2022 /PRNewswire/ -- Shanghai Stock Exchange listed company (688222.SH) H...

2022-03-17 22:30 2078

HitGen has successfully completed a three-year collaboration with MTPC to discover novel hit compounds for multiple drug targets

CHENGDU, China, Feb. 24, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STA...

2022-02-25 10:00 1554